MGC Pharmaceuticals (ASX:MXC) - Co Founder & Managing Director, Roby Zomer
Co Founder & Managing Director, Roby Zomer
Source: MGC Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MGC Pharmaceuticals (MXC) completes a successful in-vitro preclinical research study in the use of cannabinoids to treat glioblastoma
  • The study was undertaken between 2019 and 2022, initially using a formulation that included THC but was later replaced with cannabigerol (CBG)
  • Over 5800 cell tests were collected from 18 patients to determine the most effective concentrations and ratios of cannabidiol (CBD) and CBG in treatment
  • The results demonstrated the efficacy of cannabinoids in the treatment of glioblastoma and determined the most effective CBD:CBG ratio
  • MGC Pharma ends the day 35.3 per cent in the green with shares trading at 2.3 cents

MGC Pharmaceuticals (MXC) has completed a successful in-vitro preclinical research study in the use of cannabinoids to treat glioblastoma.

Glioblastoma is a fast-growing and aggressive brain tumour that can affect the brain and spine. Current treatments include radiosurgery, craniotomy, chemotherapy and radiation.

The study was undertaken between 2019 and 2022, initially using a formulation that included tetrahydrocannabinol (THC) but was later replaced with cannabigerol (CBG).

Over 5800 cell tests were collected from 18 patients to determine the most effective concentrations and ratios of cannabidiol (CBD) and CBG in treatment.

The results demonstrated the efficacy of cannabinoids in the treatment of glioblastoma and determined the most effective CBD:CBG ratio.

MGC Pharma is also undertaking studies with Graft Polymer UK PLC for the use of a base formulation nano delivery system to improve the bioavailability of the active compounds using a non-invasive drug administration process.

The studies examined the toxicity of the base emulation in order to confirm its safety profile for potential use in future clinical research.

The studies also examined the effect of adding a widely used chemotherapy agent to the treatment to determine the effect on its efficacy with the outcome demonstrating the addition had no effects to cell apoptosis (programmed cell death).

This suggests that MGC Pharma’s cannabinoid can potentially be used in further studies to determine the efficacy of its glioblastoma treatment in a clinical trial.

“The results of this trial are enormously exciting both for the company, and for the treatment of fatal cancerous tumours,” Co-Founder and Managing Director Roby Zomer said.

“MGC Pharma’s research has demonstrated the effect of naturally derived cannabinoid products on stage IV brain tumours without the use of toxic chemotherapy components.”

MGC Pharma has ended the day 35.3 per cent in the green with shares trading at 2.3 cents.

MXC by the numbers
More From The Market Herald
Cavalier Resources (ASX:CVR) - Executive Technical Director, Daniel Tuffin

" Cavalier Resources (ASX:CVR) begins PFS at Crawford

Cavalier Resources (ASX:CVR) has begun a pre-feasibility study (PFS) at the Crawford Gold Project within the…
Ten Sixty Four (ASX:X64) - Outgoing Managing Director, Paul Ryan Welker

" Ten Sixty Four (ASX:X64) terminates services agreement of former MD, Paul Ryan Welker

Ten Sixty Four (ASX:X64) has terminated the executive services agreement of former Managing Director Paul Ryan…

" M3 Mining (ASX:M3M) identifies drill targets at Edjudina

M3 Mining (ASX:M3M) has identified prospective gold-in-soil anomalies at the Edjudina gold project 150 kilometres northeast…

" Good Drinks Australia (ASX:GDA) commences the sale of Molson Coors and Magners

Good Drinks Australia (ASX:GDA) begins to sell the Miller Chill, Miller Genuine Draught, Coors, Molson Canadian…